Cara Therapeutics, Inc. (CARA)

NASDAQ: CARA · IEX Real-Time Price · USD
9.39
+0.27 (2.96%)
At close: Jun 24, 2022 4:00 PM
9.19
-0.20 (-2.13%)
After-hours: Jun 24, 2022 6:57 PM EDT
2.96%
Market Cap 503.22M
Revenue (ttm) 25.88M
Net Income (ttm) -92.89M
Shares Out 53.59M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 602,769
Open 9.26
Previous Close 9.12
Day's Range 9.04 - 9.45
52-Week Range 7.40 - 18.93
Beta 1.22
Analysts Buy
Price Target 25.50 (+171.6%)
Earnings Date Aug 8, 2022

About CARA

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialy... [Read more...]

Industry Pharmaceuticals
IPO Date Jan 31, 2014
CEO Derek Chalmers
Employees 84
Stock Exchange NASDAQ
Ticker Symbol CARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 171.57% from the latest price.

Price Target
$25.5
(171.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics Reports First Quarter 2022 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation

Cara Therapeutics to Present at May Investor Conferences

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat...

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Europe...

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Select...

Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemod...

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermati...

Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual ...

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 Americ...

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients

Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Europe...

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pa...

Cara Therapeutics To Host Virtual R&D On March 11

Joana Goncalves, MD, chief medical officer of Cara Therapeutics Brian Kim, MD, MTR,

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

Presentation to highlight oral difelikefalin Phase 3 pruritus programs Presentation to highlight oral difelikefalin Phase 3 pruritus programs

Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pa...

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

KORSUVA receives TDAPA reimbursement beginning April 2022

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical enti...

Cara Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics Reports Third Quarter 2021 Financial Results

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administratio...

Cara Therapeutics Announces CEO Transition

Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin)...

3 Explosive Biotech Stocks -- Could They Shoot Even Higher?

These biotech stocks have recently been responsible for a slew of rocketship emojis.

Other symbols: ENTAOCGN

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...